Blood Analyzers in New York

Renalytix is an AI-enabled in vitro diagnostics company specializing in chronic kidney disease (CKD) management, particularly diabetic kidney disease (DKD). The company's flagship product, KidneyIntelX.dkd, combines proprietary AI algorithms with blood-based biomarker analysis, genetic data, and electronic health record integration to generate patient risk stratification scores for progressive kidney function decline. The test received FDA marketing authorization in Q2 2023 and Medicare coverage determination in June 2024. KidneyIntelX enables early identification of high-risk patients with type 2 diabetes and CKD stages 1-3b, allowing clinicians to optimize treatment targeting and resource allocation to slow or prevent disease progression. Renalytix operates CLIA-certified clinical laboratories and partners with major healthcare systems including Mount Sinai Health System, University of Michigan, and Singing River Health System. The company also provides biomarker discovery and drug development support services to pharmaceutical partners. With a focus on shifting kidney disease management from reactive treatment to proactive health optimization, Renalytix addresses a significant public health need affecting over 850 million people globally.

ZeptoMetrix is a leading biotechnology company specializing in quality controls, assay development services, analytical reference materials, and proficiency testing for infectious disease diagnostics and analytical markets. Founded in 1999 and headquartered in Buffalo, New York, the company operates as a division of Antylia Scientific. ZeptoMetrix serves diagnostic microbiology, oncology, environmental testing, food & agriculture, cannabis & hemp, and pharmaceutical sectors. The company offers molecular controls for diagnostic testing, analytical reference materials including certified reference materials (CRMs) for environmental contaminants (PFAS, microplastics, pesticides, organotins), food safety standards, cannabis potency testing compounds, and pharmaceutical reference standards. ZeptoMetrix provides ISO 17043-accredited proficiency testing programs, viral lysates and culture fluids, seroconversion panels, monoclonal and polyclonal antibodies, ELISA kits, microbiological controls, and oncology molecular controls. With approximately 106-200 employees and ~$10M annual revenue, ZeptoMetrix serves global customers through direct sales and distributor networks, supported by comprehensive technical documentation and regulatory compliance resources.

CEIBA Health Technologies is an AI-powered healthcare technology platform specializing in virtual clinical care and medical device connectivity solutions. The company delivers an integrated Enterprise Suite with four core capabilities: (1) IoMT Interoperability—featuring a plug-and-play IoMT Box with 1,000+ pre-installed device drivers supporting 20+ EHR integrations; (2) Continuous Monitoring—delivering real-time telemetry dashboards for patient monitors, ventilators, infusion pumps, blood gas analyzers, and EEG machines across ICU, med-surge, LTACH, and SNF settings; (3) Decision Support & Workflow—providing actionable clinical insights and operational dashboards; and (4) Virtual Clinical Care—a telehealth platform enabling multi-specialty consultations, remote rounding, and acute care at home. CEIBA's protocol-agnostic architecture supports HL7, FHIR, JSON, and XML with enterprise-grade security, encrypted data transfer, and full mobile functionality. The platform is designed for rapid deployment (days vs. months) and serves hospitals and health systems in the US and internationally.